Zika Virus: Prospects for the Development of Vaccine and Antiviral Agents

Awasthi, Sita

doi:10.4172/jaa.1000e130

Cited by 8 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, two Flaviviridae (Hepatitis C and Dengue) have been found to interact with human RNASET2 protein via their NS3 protein in vitro [64]. The proteolytic domain of the ZIKV NS3 serine protease occurs at residues 1-175 [65,66], and RNASET2 is a proteolytic target at residue 24-25, which when cleaved produces a signaling peptide and the functional domain [67]. Within this functional domain exists a serine at residue 188, congruent with our predicted site of interaction (PPI-Site, residue 188-215) and four residues downstream of the leukoencephalopathy-associated mutation.…”

Section: Discussionmentioning

confidence: 99%

Designing anti-Zika virus peptides derived from predicted human-Zika virus protein-protein interactions

Kazmirchuk

Dick

Burnside

et al. 2017

Computational Biology and Chemistry

View full text Add to dashboard Cite

The production of anti-Zika virus (ZIKV) therapeutics has become increasingly important as the propagation of the devastating virus continues largely unchecked. Notably, a causal relationship between ZIKV infection and neurodevelopmental abnormalities has been widely reported, yet a specific mechanism underlying impaired neurological development has not been identified. Here, we report on the design of several synthetic competitive inhibitory peptides against key pathogenic ZIKV proteins through the prediction of protein-protein interactions (PPIs). Often, PPIs between host and viral proteins are crucial for infection and pathogenesis, making them attractive targets for therapeutics. Using two complementary sequence-based PPI prediction tools, we first produced a comprehensive map of predicted human-ZIKV PPIs (involving 209 human protein candidates). We then designed several peptides intended to disrupt the corresponding host-pathogen interactions thereby acting as anti-ZIKV therapeutics. The data generated in this study constitute a foundational resource to aid in the multi-disciplinary effort to combat ZIKV infection, including the design of additional synthetic proteins.

show abstract

Section: Discussionmentioning

confidence: 99%

Designing anti-Zika virus peptides derived from predicted human-Zika virus protein-protein interactions

Kazmirchuk

Dick

Burnside

et al. 2017

Computational Biology and Chemistry

View full text Add to dashboard Cite

show abstract

“…It is possible to develop as single vaccine that is effective against all circulating strains of ZIKV because of low strain diversity of ZIKV [77] . Given sufficient resources, it is reasonable to estimate that candidate ZIKV vaccines could be available for clinical evaluation in 2017 [78] .…”

Section: Zikv Vaccine Strategiesmentioning

confidence: 99%

“…The RO5 compliant and toxicophore-negative lead compounds identified in the study offer a rationale for rapid verification in ZIKV cell culture models for drug discovery [97] . Broad-spectrum antiviral drug that can target diverse flaviviruses including ZIKV is being developed under the research project funded by National Institute of Health [77].…”

Section: Future Strategiesmentioning

confidence: 99%

Advances in research on Zika virus

Ali

Wahid

Rafique

et al. 2017

Asian Pacific Journal of Tropical Medicine

View full text Add to dashboard Cite

Zika virus (ZIKV) is rapidly spreading across the America and its devastating outcomes for pregnant women and infants have driven this previously ignored pathogen into the limelight. Clinical manifestations are fever, joint pain or rash and conjunctivitis. Emergence of ZIKV started with a first outbreak in the Pacific area in 2007, a second large outbreak occurred in the Pacific in 2013/2014 and subsequently the virus spread in other Pacific islands. Threat of explosive global pandemic and severe clinical complications linked with the more immediate and recurrent epidemics necessitate the development of an effective vaccine. Several vaccine platforms such as DNA vaccine, recombinant subunit vaccine, ZIKV purified inactivated vaccine, and chimeric vaccines have shown potent efficacy in vitro and in vivo trials. Moreover, number of drugs such as Sofosbuvir, BCX4450, NITD008 and 7-DMA are ready to enter phase I clinical trial because of proven anti-ZIKV activity. Monoclonal based antibodies offer promise as an intervention effective for use in pregnant women. In this review, we describe the advances in research on ZIKV such as research strategies for the development of antiviral drugs & vaccines, molecular evolution, epidemiology emergence, neurological complications and other teratogenic outcomes as well as pathogenesis.

show abstract

“…The ZIKV vaccine can be effectively designed for all the circulating viral strains due to lesser variations reported among the strains (Awasthi, 2016). For Asian-lineage ZIKV, the immune response induced in Indian-origin rhesus macaques against the infecting strain was found to protect from re-infection with homologous viral strain revealing broader immunity .…”

Section: Vaccinesmentioning

confidence: 99%

Zika Virus / Zika Fever : A Comprehensive Update

Dhama¹,

Karthik²,

Tiwari³

et al. 2018

JEBAS

View full text Add to dashboard Cite

Zika virus (ZIKV) has attracted global attention after its first large-scale outbreak in Pacific, Micronesian island of Yap (Year 2007). The virus spreads rapidly and owes increased virulence than the ZIKV which appeared nearly six decades ago, where it was associated with sporadic cases and mild illness. The World Health Organization declared ZIKA as a "Public Health Emergency of International Concern" due to severe illness and associated several complications such as neurological disorders, autoimmune disorder, fetal anomalies, impaired central nervous system (CNS) of the fetus, microcephaly

show abstract

Zika Virus: Prospects for the Development of Vaccine and Antiviral Agents

Cited by 8 publications

References 19 publications

Designing anti-Zika virus peptides derived from predicted human-Zika virus protein-protein interactions

Designing anti-Zika virus peptides derived from predicted human-Zika virus protein-protein interactions

Advances in research on Zika virus

Zika Virus / Zika Fever : A Comprehensive Update

Contact Info

Product

Resources

About